---
title: acute promyelocytic leukemia (APL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> 🌱 來自: [[acute myelogenous leukemia (AML)]]

# acute promyelocytic leukemia (APL)

(Blood 2009;113:1875)

Rare,
~8% of AML in U.S.

> 90% cure rates

- Atypical promyelocytes (large, granular cells; [[bilobed nuclei]]) in blood and bone marrow

- Defined by translocation of retinoic acid receptor: **t(15;17); PML-RARA** (>95% of cases)

- **Medical emergency** with **DIC** and **bleeding** common

- Remarkable responses to **[[all-trans-retinoic acid]] (ATRA)** & **arsenic trioxide (ATO)** which induce differentiation of leukemic blasts.
  - ∴ **_early initiation of ATRA if APL suspected_**

## Non-high-risk APL 🍏

- ATRA + ATO (induction + 4 cycles consolidation)
- → CR ~100%;
- event-free survival 97% and overall survival 99% at 2 y (NEJM 2013;362:111)

## High-risk APL 🍎

- WBC >10k at diagnosis.
- No clear consensus.
- In general, chemo (anthracycline or gemtuzumab ozogamicin) added to ATRA + ATO induction and consolidation.

## [[Differentiation syndrome]] (ATRA)
